GoHealth receives Nasdaq minimum bid price deficiency notice; appoints David Fisher to board

GoHealth, Inc.

Received Nasdaq notice for bid price below $1.00 for 30 consecutive days; compliance period through Nov 21, 2022.
Company may pursue reverse stock split to regain compliance, subject to board and stockholder approval.
David Fisher appointed as Class I director and Audit Committee chair; Helene Gayle resigned with no disagreement.
At annual meeting, stockholders approved all proposals: directors, EY ratification, say-on-pay every year, plan amendment.

item 3.01 item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David Fisher

Class I Director

GOCO · GoHealth, Inc.

Effective: 2022-05-25
Successor: Helene D. Gayle
Filed: May 27, 2022, 7:59 PM ET

the Board of the Company appointed David Fisher as a Class I director to fill the vacancy created by Helene D. Gayle

Departed

Helene D. Gayle

Director

GOCO · GoHealth, Inc.

Effective: 2022-05-25
Successor: David Fisher
Filed: May 27, 2022, 7:59 PM ET

Helene D. Gayle, who resigned from the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Fisher was appointed as Class I Director at GoHealth, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

the Board of the Company appointed David Fisher as a Class I director to fill the vacancy created by Helene D. Gayle

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Helene D. Gayle resigned as Director at GoHealth, Inc..

Action: resigned
Role: Director

Exact text from the filing

Helene D. Gayle, who resigned from the Board

View on SEC.gov

GoHealth, Inc. filing history →

Source: SEC EDGAR

accession 0001808220-22-000052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.